We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024 Les données de...
Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced...
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Compelling 24.1-month median follow-up data...
Transgene fait le point sur ses activités, son portefeuille et sa situation financière au troisième trimestre 2024 TG4050 : Données prometteuses de Phase I présentées au SITC 2024 confirmant une...
Transgene Reports Business, Pipeline and Financial Update for Q3 2024 TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck...
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET—Transgene (Euronext Paris: TNG), a...
Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of...
Transgene et ProBioGen collaborent pour faire progresser le développement des vaccins thérapeutiques individualisés Strasbourg (France), Berlin (Germany), le 5 novembre 2024, 7 h 30 Transgene...
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers Top line data show that the randomized...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -5.96658711217 | 0.838 | 0.838 | 0.76 | 29161 | 0.78748416 | DE |
4 | -0.138 | -14.9028077754 | 0.926 | 0.964 | 0.76 | 40513 | 0.86634154 | DE |
12 | -0.34 | -30.1418439716 | 1.128 | 1.204 | 0.76 | 34859 | 0.98604941 | DE |
26 | -0.536 | -40.4833836858 | 1.324 | 1.35 | 0.76 | 30040 | 1.05785457 | DE |
52 | -0.662 | -45.6551724138 | 1.45 | 1.52 | 0.76 | 29773 | 1.17604595 | DE |
156 | -1.622 | -67.3029045643 | 2.41 | 2.99 | 0.76 | 38046 | 1.92820697 | DE |
260 | -1.022 | -56.4640883978 | 1.81 | 3.15 | 0.76 | 74399 | 1.98395186 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions